{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Glycopyrrolate&page=4",
    "query": {
      "intervention": "Glycopyrrolate",
      "page": 4
    },
    "page_size": 10
  },
  "pagination": {
    "page": 4,
    "page_size": 10,
    "total_count": 97,
    "total_pages": 10,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Glycopyrrolate&page=5&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Glycopyrrolate&page=3&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-04T08:41:49.243Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03162055",
      "title": "Efficacy and Safety of Glycopyrronium/Formoterol Fumarate Fixed-dose Combination Relative to Umeclidinium/Vilanterol Fixed-dose Combination Over 24 Weeks in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Obstructive Pulmonary Disease COPD"
      ],
      "interventions": [
        {
          "name": "Glycopyrronium/Formoterol Fumarate",
          "type": "DRUG"
        },
        {
          "name": "umeclidinium/vilanterol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "95 Years",
        "sex": "ALL",
        "summary": "40 Years to 95 Years"
      },
      "enrollment_count": 1119,
      "start_date": "2017-05-25",
      "completion_date": "2018-05-04",
      "has_results": true,
      "last_update_posted_date": "2019-05-22",
      "last_synced_at": "2026-10-04T08:41:49.243Z",
      "location_count": 15,
      "location_summary": "Tempe, Arizona • Escondido, California • Sacramento, California + 12 more",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Escondido",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Hollywood",
          "state": "Florida"
        },
        {
          "city": "Lawrenceville",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03162055"
    },
    {
      "nct_id": "NCT02370433",
      "title": "Use of Prokinetics During Inpatient Bowel Care for SCI Patients",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Spinal Cord Injury",
        "Neurogenic Bowel"
      ],
      "interventions": [
        {
          "name": "Intravenous Neostigmine and Glycopyrrolate",
          "type": "DRUG"
        },
        {
          "name": "Transdermal Neostigmine and Glycopyrrolate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "James J. Peters Veterans Affairs Medical Center",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 20,
      "start_date": "2012-12",
      "completion_date": "2018-12",
      "has_results": false,
      "last_update_posted_date": "2017-08-29",
      "last_synced_at": "2026-10-04T08:41:49.243Z",
      "location_count": 1,
      "location_summary": "The Bronx, New York",
      "locations": [
        {
          "city": "The Bronx",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02370433"
    },
    {
      "nct_id": "NCT03250182",
      "title": "A Study to Assess the PK and Safety of PT010 in Subjects With COPD Following Single and Repeat Dose",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Chronic Obstructive Pulmonary Disease"
      ],
      "interventions": [
        {
          "name": "PT010",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pearl Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "40 Years to 80 Years"
      },
      "enrollment_count": 30,
      "start_date": "2017-08-11",
      "completion_date": "2017-12-07",
      "has_results": true,
      "last_update_posted_date": "2021-01-29",
      "last_synced_at": "2026-10-04T08:41:49.243Z",
      "location_count": 1,
      "location_summary": "Clearwater, Florida",
      "locations": [
        {
          "city": "Clearwater",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03250182"
    },
    {
      "nct_id": "NCT03081156",
      "title": "The Effect of BEVESPI AEROSPHERE ® Therapy on Exercise Tolerance in COPD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Pulmonary Disease, Chronic Obstructive"
      ],
      "interventions": [
        {
          "name": "Glycopyrrolate / Formoterol Inhaler vs Placebo Inhaler",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "William Stringer, md",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "40 Years to 80 Years"
      },
      "enrollment_count": 52,
      "start_date": "2017-03-27",
      "completion_date": "2019-01-31",
      "has_results": true,
      "last_update_posted_date": "2025-10-21",
      "last_synced_at": "2026-10-04T08:41:49.243Z",
      "location_count": 1,
      "location_summary": "Torrance, California",
      "locations": [
        {
          "city": "Torrance",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03081156"
    },
    {
      "nct_id": "NCT02038829",
      "title": "A Dose-Range Finding Study of SUN-101 in Subjects With Moderate to Severe COPD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "COPD"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "SUN101 3 mcg",
          "type": "DRUG"
        },
        {
          "name": "SUN-101 6.25 mcg",
          "type": "DRUG"
        },
        {
          "name": "SUN-101 12.5 mcg",
          "type": "DRUG"
        },
        {
          "name": "SUN-101 50 mcg",
          "type": "DRUG"
        },
        {
          "name": "Aclidinium",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sunovion Respiratory Development Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "40 Years to 65 Years"
      },
      "enrollment_count": 96,
      "start_date": "2014-01",
      "completion_date": "2014-05",
      "has_results": true,
      "last_update_posted_date": "2018-04-10",
      "last_synced_at": "2026-10-04T08:41:49.243Z",
      "location_count": 10,
      "location_summary": "Clearwater, Florida • Charlotte, North Carolina • Raleigh, North Carolina + 5 more",
      "locations": [
        {
          "city": "Clearwater",
          "state": "Florida"
        },
        {
          "city": "Charlotte",
          "state": "North Carolina"
        },
        {
          "city": "Raleigh",
          "state": "North Carolina"
        },
        {
          "city": "Medford",
          "state": "Oregon"
        },
        {
          "city": "Easley",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02038829"
    },
    {
      "nct_id": "NCT02524145",
      "title": "Chronotropic Incompetence in Patients With HFpEF",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Heart Failure"
      ],
      "interventions": [
        {
          "name": "Static Handgrip",
          "type": "OTHER"
        },
        {
          "name": "Dexmedetomidine",
          "type": "DRUG"
        },
        {
          "name": "Glycopyrrolate",
          "type": "DRUG"
        },
        {
          "name": "Isoproterenol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "University of Texas Southwestern Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 40,
      "start_date": "2015-06",
      "completion_date": "2017-11-15",
      "has_results": true,
      "last_update_posted_date": "2020-08-06",
      "last_synced_at": "2026-10-04T08:41:49.243Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02524145"
    },
    {
      "nct_id": "NCT02268396",
      "title": "Glycopyrronium and Formoterol Fumarate (GFF) Metered Dose Inhaler (MDI) Dose Indicator Study in Adults With Moderate to Very Severe COPD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "COPD"
      ],
      "interventions": [
        {
          "name": "Glycopyrronium and Formoterol Fumarate Metered-dose Inhaler",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pearl Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "40 Years to 80 Years"
      },
      "enrollment_count": 138,
      "start_date": "2014-11",
      "completion_date": "2015-05",
      "has_results": true,
      "last_update_posted_date": "2016-12-23",
      "last_synced_at": "2026-10-04T08:41:49.243Z",
      "location_count": 10,
      "location_summary": "Clearwater, Florida • Tampa, Florida • Winter Park, Florida + 7 more",
      "locations": [
        {
          "city": "Clearwater",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Winter Park",
          "state": "Florida"
        },
        {
          "city": "Charlotte",
          "state": "North Carolina"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02268396"
    },
    {
      "nct_id": "NCT05887375",
      "title": "Sugammadex vs Neostigmine/Glycopyrrolate on Urinary Retention After Spine Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Spine Surgery",
        "Reversal of Neuromuscular Blockade",
        "Urinary Retention Postoperative"
      ],
      "interventions": [
        {
          "name": "Sugammadex",
          "type": "DRUG"
        },
        {
          "name": "Neostigmine",
          "type": "DRUG"
        },
        {
          "name": "Glycopyrrolate",
          "type": "DRUG"
        },
        {
          "name": "Rocuronium",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Missouri-Columbia",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 118,
      "start_date": "2023-08-03",
      "completion_date": "2026-01-15",
      "has_results": false,
      "last_update_posted_date": "2026-05-05",
      "last_synced_at": "2026-10-04T08:41:49.243Z",
      "location_count": 1,
      "location_summary": "Columbia, Missouri",
      "locations": [
        {
          "city": "Columbia",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05887375"
    },
    {
      "nct_id": "NCT06067828",
      "title": "A Study to Evaluate the Effect of Budesonide, Glycopyrronium, Formoterol Fumarate (BGF) Metered Dose Inhaler (MDI), Budesonide and Formoterol Fumarate (BFF) MDI and Placebo MDI on Exercise Parameters in Participants With Chronic Obstructive Pulmonary Disease (COPD).",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Obstructive Pulmonary Disease"
      ],
      "interventions": [
        {
          "name": "Treatment A : Budesonide, Glycopyrronium, and Formoterol Fumarate",
          "type": "DRUG"
        },
        {
          "name": "Treatment B: Budesonide and Formoterol Fumarate",
          "type": "DRUG"
        },
        {
          "name": "Treatment C : Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "40 Years to 80 Years"
      },
      "enrollment_count": 171,
      "start_date": "2023-10-24",
      "completion_date": "2026-01-22",
      "has_results": false,
      "last_update_posted_date": "2026-03-05",
      "last_synced_at": "2026-10-04T08:41:49.243Z",
      "location_count": 7,
      "location_summary": "Los Angeles, California • Tarzana, California • Torrance, California + 4 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Tarzana",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Brooksville",
          "state": "Florida"
        },
        {
          "city": "Anderson",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06067828"
    },
    {
      "nct_id": "NCT07016412",
      "title": "Clinical Study of Ensifentrine-Glycopyrrolate (MK-5884A/RPL554) Fixed-dose Combination Dose Ranging in Participants With COPD (MK-5884A-029/RPL554-CO-212)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Obstructive Pulmonary Disease"
      ],
      "interventions": [
        {
          "name": "Ensifentrine 3 mg",
          "type": "DRUG"
        },
        {
          "name": "Glycopyrrolate 21.25 mcg",
          "type": "DRUG"
        },
        {
          "name": "Glycopyrrolate 42.5 mcg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "40 Years to 80 Years"
      },
      "enrollment_count": 497,
      "start_date": "2025-07-31",
      "completion_date": "2026-08-17",
      "has_results": false,
      "last_update_posted_date": "2026-09-11",
      "last_synced_at": "2026-10-04T08:41:49.243Z",
      "location_count": 57,
      "location_summary": "Dothan, Alabama • Phoenix, Arizona • Tucson, Arizona + 49 more",
      "locations": [
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Northridge",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07016412"
    }
  ]
}